Evaluating the anticancer properties of VAF: a novel folate-α-tocopherol conjugate against lung cancer cells

In this study, a new chemical folate conjugated to α-tocopherol (VAF) is introduced. The main goal is to investigate the potential of VAF as a strong anticancer agent. This improves the drug-targeting delivery system and lessens the negative effects associated with traditional chemotherapy.

To synthesize VAF, α-tocopherol, and folic acid were linked by a peptide bond, creating an amphiphilic structure that allowed for self-assembly in aqueous conditions. With an emphasis on evaluating VAF's capacity to target folate receptors, In vitro experiments were carried out utilizing A549 lung cancer cells to assess the anticancer effects of VAF.

VAF was synthesized under mild circumstances, and its characterization was carried out using many analytical techniques, such as FTIR spectroscopy and NMR. In vitro investigations showed that VAF's improved active targeting via folate receptors results in excellent anticancer effects. Additionally, the cell viability of Wi-38 and A549 was assessed by using confocal laser scanning microscopy (CLSM).

According to the research, VAF reduces the possibility of adverse effects while increasing the efficacy of anticancer treatments. The compound exhibits promising properties that make it a great option for additional research and development in cancer treatments. Research provides important new information about drug-targeting delivery systems and improves a potentially useful method for anticancer drug therapeutic indices.